Author: Sitryx Therapeutics

Posted Date:

May 18, 2026

Sitryx to Participate in Upcoming Investor Conferences

Sitryx Therapeutics

May 18, 2026
First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026

Sitryx Therapeutics

May 13, 2026
Sitryx nominates novel, oral GLS1 inhibitor for clinical development in moderate to severe asthma

Sitryx Therapeutics

May 4, 2026
Sitryx to participate in upcoming April investor conferences

Sitryx Therapeutics

May 4, 2026
Sitryx to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Sitryx Therapeutics

February 19, 2026
Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity

Sitryx Therapeutics

February 3, 2026